nwinnovation
High Technology News and Information for the Pacific Northwest Region
Home
Mobile
News and Events
  • Headlines
  • Interviews
  • Events
  • Jobs
  • VC Funds
    		•
    Members Only
  • Networking
  • Venture Deals
  • Venture Firms
  • Companies
  • People
  • Exits
  • VentureMap
  • PowerSearch
  • FundingSearch
  • Stats
  • Dashboard
  • Satellite
  • Post Jobs
    • About
  • About
  • Contact Us
    		•
    Search News
    Subscribe with Bloglines Subscribe in NewsGator Online Add to My Yahoo
    Thursday, May 15, 2008

    Fate Therapeutics Adds CEO, Chairman


    Seattle-based biopharmaceutical firm Fate Therapeutics reported Wednesday that it has hired Paul A. Grayson as president and chief executive officer and appointed John Mendlein as executive chairman. Prior to joining Fate Therapeutics, Grayson was managing director of Sanderling Ventures. He has also served as chairman of Naviscan PET Systems and CalciMedica's board of directors. Until recently, Mendlein was CEO of Adnexus Therapeutics, which Bristol-Myers Squibb Co. acquired for more than $505 million in October 2007. Founded in early 2007, Fate Therapeutics is a private held company that has raised more than $15 million in venture financing from ARCH Venture Partners, Polaris Venture Partners, Venrock, OVP and other investors.
    posted on Thursday, May 15, 2008


    Related companies:
    Fate Therapeutics

    Related stories:
    > Fate Therapeutics Launches Stem Cell Firm
    > CG Therapeutics Appoints Chairman, Looks For Venture Funding
    > Ikaria Buys INO Therapeutics For $670M
    > Cell Therapeutics to Nab Systems Medicine for $20M
    > Nastech Cuts 50
    Sign up to receive updates via our daily email newsletter

    Enter your email:


    Previous Issues

     Thursday, July 24, 2008
    Wednesday, July 23, 2008
    Tuesday, July 22, 2008
    Monday, July 21, 2008
    Friday, July 18, 2008